Travere Therapeutics, Inc. TVTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
5/9
Piotroski F — financial health
-5.38
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $490.7M | -$25.5M | — | — | $114.8M |
| 2024 | $233.2M | -$321.5M | — | — | $59.1M |
| 2023 | $145.2M | -$111.4M | — | -$326.0M | $200.8M |
| 2022 | $109.5M | -$278.5M | — | -$186.5M | $42.9M |
| 2021 | $131.8M | -$180.1M | — | -$81.3M | $302.1M |
| 2020 | $198.3M | -$169.4M | — | -$49.5M | $211.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Inrig Jula | CHIEF MEDICAL OFFICER | 2026-06-22 | Gift | 468 | — |
| Coughlin Timothy | director | 2026-06-12 | Option exercise | 10,000 | $26.52 |
| Coughlin Timothy | director | 2026-06-12 | Sell | 10,000 | $50.07 |
| Baynes Roy D. | director | 2026-06-12 | Option exercise | 4,500 | $21.38 |
| Baynes Roy D. | director | 2026-06-12 | Sell | 4,500 | $50.00 |
| Williams Brinkley Ruth | director | 2026-05-19 | Grant | 4,000 | — |
| Squarer Ron | director | 2026-05-19 | Grant | 4,000 | — |
| Poole Sandra | director | 2026-05-19 | Grant | 4,000 | — |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -5.38 (distress)
- Working capital / assets 0.459
- Retained earnings / assets -2.433
- EBIT / assets -0.104
- Equity / liabilities 0.234
Source: SEC EDGAR filings · CIK 0001438533 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.